Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Claudin-6 (CLDN6)
- Target
- CLDN6
- Molecular classification
- Claudin family, Multipass transmembrane protein
01
Overview
Claudin-6 (CLDN6) is a transmembrane protein that is an essential component of tight junctions, regulating paracellular permeability and maintaining cell polarity. It is primarily expressed during embryonic development and exhibits limited expression in most adult tissues under normal physiological conditions. Aberrant CLDN6 activation is observed in certain cancers, making it an attractive target for cancer therapy. Therapeutically targeting CLDN6 requires high specificity to avoid off-target effects due to sequence similarity with other claudins.
- Other names
- SkullinSkullin 2Claudin6
02
Mechanism of action
Chimeric antigen receptor T-cell (CAR-T) therapies targeting CLDN6
03
Biological functions
Tight junction formationParacellular barrier regulationCell-to-cell adhesionRegulation of nuclear receptor activityReceptor for hepatitis C virus entrySignal transmission involving cytoskeletal proteinsTissue development
04
Disease associations
Cancer
05
Safety considerations
Off-target effects due to high sequence similarity with other claudins, especially CLDN9Potential side effects like hearing loss or liver enzyme elevations if selectivity is insufficient
06
Biomarkers
CLDN6 overexpression in non-small cell lung carcinoma (NSCLC)CLDN6 overexpression in testicular cancerCLDN6 overexpression in ovarian cancerCLDN6 overexpression in intestinal-type gastric cancer
Beyond the preview
Go deeper on Claudin-6 (CLDN6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claudin-6 (CLDN6).